Introduction
Bronchiectasis is a chronic inflammatory respiratory disease characterized by bronchial dilatation, and symptoms of productive cough, dyspnoea and repeated respiratory infections requiring frequent courses of antibiotics. 1 Infective exacerbations are important insults to the lungs that may contribute to incremental loss of lung function and affect patients' quality of life [2] [3] [4] and survival. [5] [6] [7] The mainstay of treatment for patients with a bronchiectasis exacerbation is antibiotic treatment and physiotherapy. Current Cochrane reviews indicate a paucity of evidence for the efficacy of treatments given to patients with noncystic fibrosis bronchiectasis, 8 although long-term low-dose macrolide maintenance therapy is effective in preventing exacerbations. [9] [10] [11] [12] [13] Vitamin D has an important role in modulating innate immunity. In recent years, vitamin D supplementation has been shown to reduce the incidence of acute asthma exacerbations, 14 acute respiratory infections 15 and chronic obstructive pulmonary disease (COPD) exacerbations. 16 Bronchiectasis severity is associated with low 25-hydroxyvitamin D (25(OH)D) levels. 17 The role of vitamin D supplementation in bronchiectasis management is not known.
The primary aims of this pilot study were to assess serum 25(OH)D levels in a cohort of New Zealand adults with bronchiectasis, and the effect of vitamin D 3 supplementation on their 25(OH)D levels.
Methods
We enrolled patients in an open-label trial in Auckland (latitude 36 S), New Zealand between 14 April 2014 and 23 March 2015 ( Figure 1 ). Patients were eligible for inclusion if they were aged !18 and 80 years, were clinically stable over the previous 4 weeks, had had at least one pulmonary exacerbation requiring antibiotic treatment in the past year and had a diagnosis of bronchiectasis defined by highresolution chest computed tomography (CT) scan (<2 years old). Bronchiectasis severity on highresolution chest CT scans was scored using the Bhalla index 18 and CT scan sinus disease (<2 years old) was scored using the Lund-Mackay system. 19 Exclusion criteria were a diagnosis of cystic fibrosis, hypogammaglobulinaemia or allergic bronchopulmonary aspergillosis; a positive culture of non-tuberculous mycobacteria in the past 2 years or at screening; macrolide treatment for more than 3 months in the previous 6 months; current vitamin D supplementation (including cod liver oil) of >600 IU per day; history of renal stones or hypercalcaemia; consumption of medications that affect vitamin D metabolism (e.g. anti-epileptic or tuberculosis medication) or unstable arrhythmia. Participants provided written informed consent. The study was approved by the Northern A Health and Disability Ethics Committee.
Patients had an initial screening visit (Table 1 ) when forced expiratory volume in 1 second (FEV 1 ) and forced vital capacity (FVC) before and after bronchodilation were assessed. Serum 25(OH)D levels were assessed at the screening visit and 12 and 24 weeks after treatment initiation. Blood samples were collected and stored at À70 C until serum 25(OH)D levels (primary outcome) were measured.
Secondary outcomes included: serum C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and neutrophil count assessed at the initial screening visit and at 12 and 24 weeks. Nasal endoscopy 19, 20 was performed (JB), and sputum samples for 25(OH)D levels, cathelicidin levels, cell counts and culture of respiratory pathogens were obtained at the initial screening visit and at 24 weeks (Table 1) . Every sputum sample was dispersed with dithiothreitol and filtered, and total cell count and viability assessed. The cell suspensions were centrifuged, and cytospins prepared. Serum and sputum 25(OH)D levels were measured using a competitive electro chemiluminescence assay kit (Elecsys, Roche Diagnostics, Burgess Hill, UK) and cathelicidin in serum and sputum was measured using the Human LL-37 ELISA Test Kit (Hycult Biotechnology, HK321, Uden, The Netherlands) according to manufacturer instructions. The products were manufactured at ISO certified facilities. All assays were performed in duplicate and included internal standards used to construct standard curves for analyte concentration assessment.
Four weeks later at the baseline visit, patients received an initial oral loading dose of 2.5 mg (100,000 IU) vitamin D 3 . Patients were given capsules of 0.625 mg (25,000 IU) vitamin D 3 every week for 24 weeks. Patients confirmed the intake of test medication in their diary card. If patients missed a dose, they were instructed to take the missed dose on the following day and to make a note of this in their diary card. FEV 1 and FVC before and after bronchodilation were repeated. Two health-related quality of life (HRQL) measures -the Leicester Cough Questionnaire (LCQ) 21 and the Dartmouth COOP charts 22 and the 20-Item Sino-Nasal Outcome Test (SNOT-20) 19 were administered and repeated at 24 weeks (Table 1) .
The patients were contacted regularly by telephone at 2 weeks before treatment and 4, 8, 16 and 20 weeks after treatment had been initiated ( Table 1 ). The time to first exacerbation and exacerbation frequency over 24 weeks was also assessed. An event-based exacerbation was defined as an increase in or new onset of more than one pulmonary symptom (sputum volume, sputum purulence or dyspnoea) for 48 hours or more, requiring treatment with antibiotics. This study is registered with the Australian New Zealand Clinical Trials Registry (ACTRN 12607000641493).
Statistical analysis Primary outcomes
The primary outcome (serum 25(OH)D level) was first analysed using McNemar's test. A linear mixed model was then fitted to produce estimated differences in mean concentration from baseline and each subsequent time point that serum 25(OH)D was measured.
Correlations at baseline
Correlations between all measurements at the screening and baseline visits were estimated and tested against a null value of 0. Nominal 95% confidence intervals (CIs) were produced, along with False Discovery Rate (FDR) -adjusted p values.
Secondary outcomes -repeated measures
A linear mixed model was fitted to secondary outcomes, which were measured at more than one-time point post-baseline (Table 1 ). All repeated measures were regressed on time point (included as a factor). The model included a random effect for each participant, accounting for dependence between observations made on the same individual. The structure of the random effects and covariance was selected using Akaike's information criterion, and the preferred model allows for the estimation of two separate variances: one for time points at which patients were 
Missing baseline and outcome data
Missing baseline and outcome data resulted in case-wise deletion of the record, and analyses were performed using a complete-case analysis. Baseline was modelled as a repeated measure in the mixed models; these models accommodate case-wise deletion by default.
Results
Thirty-three patients were recruited to the pilot study (Table 2) , completing an initial screening visit at 4 weeks and follow-up assessment at baseline, 12 and 24 weeks. Two patients with a bronchiectasis diagnosis did not have bronchiectasis on high-resolution chest CT scans. One enrolled patient dropped out of the study prior to the 12-week assessment. The average non-missing adherence (pills taken/target) was 93% at 12 weeks and 92% at 24 weeks. The proportion of missing data on adherence was 22% (7 participants) at visit 3 and 16% (5 participants) at visit 4. No significant adverse effects were recorded. 
Correlations at baseline

Primary outcome analysis
The initial, average 25(OH)D level was 71 nmol/L. Vitamin D 3 supplementation significantly increased serum 25(OH)D levels (p < 0.001). Two subjects had (Table 3) .
Secondary outcomes analysis
From baseline to 24 weeks, no significant change occurred in pre-bronchodilator FEV 1 There were a total of 37 respiratory exacerbations over the 24 weeks (Figure 2 The fitted model (Table 3) shows a statistically significant improvement in the LCQ from baseline to 24 weeks, with an increase of 1.11 (95% CI: [0.08, 2.14]) and a statistically significant decrease in the Dartmouth COOP charts score from baseline to 24 
Discussion
The primary aims of this pilot study were to assess serum 25(OH)D levels in New Zealand adults with bronchiectasis, and their 25(OH)D levels after vitamin D 3 supplementation. The initial, average 25(OH)D level in this patient population was 71 nmol/L, which was higher than reported previously in the New Zealand adult population 23 and in a Scottish bronchiectasis population, 17 but in keeping with the average 25(OH)D level in a recent New Zealand study investigating vitamin D 3 supplementation in upper respiratory infection prevention. 24 An initial vitamin D 3 bolus dose (100,000 IU) and weekly vitamin D 3 doses (25,000 IU) increased the average 25(OH)D level to 218 nmol/L at 3 months and 205 nmol/L at 6 months, a response consistent with the literature. 25 This vitamin D 3 supplementation dose was chosen, because it was anticipated that the 25(OH) levels in an adult New Zealand bronchiectasis population would be lower 17, 23 and that with ongoing infection/inflammation, a standard oral vitamin D 3 supplementation dose could be inadequate. 26 A weekly vitamin D 3 supplementation regimen was adopted, because initial meta-analysis evidence indicated that a monthly bolus dose was ineffective in respiratory infection prevention 27 and to improve patient compliance. A recent meta-analysis has confirmed the efficacy of weekly vitamin D supplementation in respiratory infection prevention. 15 Vieth has proposed that high circulating concentrations after bolus dosing may chronically cause inappropriately low 1-alpha-hydroxylase activity coupled with inappropriately high 24-hydroxylase activity, which may limit local concentrations of the active vitamin D metabolite 1,25-dihydroxyvitamin D, resulting in decreased concentrations of this metabolite in extrarenal tissues. 28 Vitamin D 3 may itself play an important physiological role, although the half-life of this compound is only approximately 24 hours. 29 The optimal anti-infective serum 25(OH)D level remains to be determined. Among those receiving daily or weekly vitamin D, the protective effects appear stronger when 25(OH)D levels are less than 25 nmol/L although those with higher baseline 25(OH)D concentrations also experience benefit. 15 A U-shaped relationship between serum 25(OH)D and the risk of tuberculosis has been reported. 30 However, observational studies report that serum 25(OH)D levels >75nmol/ L or >96 nmol/L are associated with protection against acute respiratory infection. 31, 32 In the Third National Health and Nutrition Examination Survey, a strong association between serum 25(OH)D, FEV 1 and FVC was observed. 33 In asthmatic patients, serum 25(OH)D levels are associated with decline in lung function. 34 In this pilot study, no significant correlation between screening serum 25(OH)D and baseline FEV 1 or FVC was observed. From baseline to 24 weeks, no significant change in pre-bronchodilator and post-bronchodilator FEV 1 or FVC was detected, a finding consistent with macrolide studies in bronchiectasis. 13 Although the small sample size limited statistical power, secondary outcomes were collected to help with designing a future randomized controlled trial. Secondary aims included measuring time to first exacerbation and exacerbation frequency after vitamin D 3 supplementation. There were a total of 37 respiratory exacerbations across all study participants over the duration of the study. No significant association was found between serum 25(OH)D levels and frequency or severity of exacerbations, but our study was not powered to detect effects on exacerbation frequency.
Serum cathelicidin also increased significantly. The estimated increase from the screening visit to 12 weeks was 77 and 126 ng/ml from the screening visit to 24 weeks. After 24 weeks of treatment, no significant change was seen in serum ESR, serum CRP, neutrophil count, sputum 25(OH)D or cathelicidin levels. Thijs et al. observed a similar result in the assessment of vitamin D supplementation on nasal antimicrobial peptide (AMP) levels. 35 After 24 weeks of treatment, no significant change was seen in sputum neutrophil levels. In non-atopic asthma, vitamin D reduces eosinophil count but not neutrophil count. 36 After 24 weeks of treatment, no major change was seen in sputum microbiology.
Two previous studies have assessed the potential co-morbidity between chronic rhinosinusitis (CRS) and bronchiectasis. 37, 38 CRS disease severity is also associated with low 25(OH)D levels. 39 While no significant change was seen in the SNOT-20 score, the nasal endoscopy score improved significantly with a reduction of À1.27 (95% CI: [À1.54, À0.99], p < 0.01). The SNOT-20 score is a more reliable measure of sinus symptoms and response to treatment than nasal endoscopy. Interobserver variation in nasal endoscopy has been observed. 20 This finding may be a spurious result, yet any such improvement in nasal endoscopic findings could be relevant clinically.
Improving patients' HRQL is a major goal of disease management. The LCQ is validated in bronchiectasis and is responsive to change . 21, 40 In our pilot study, a statistically significant improvement in the LCQ occurred, but this did not reach the threshold for a clinically important difference of 1.3. 41 The Dartmouth COOP charts score is a reliable, easy to administer HRQL tool, which is valid and responsive in COPD patients. 22 We found a statistically significant improvement in the Dartmouth COOP score, although this is not a validated score in bronchiectasis. Some patients appeared to have obtained clinical benefit from vitamin D 3 supplementation. A small pilot study of vitamin D supplementation in cystic fibrosis patients has also shown an improvement in HRQL respiratory score. 42 To our knowledge, this pilot study is the first to investigate the potential role of vitamin D 3 supplementation in bronchiectasis management. New Zealand adults with bronchiectasis had higher than expected initial 25(OH)D levels and a standard oral vitamin D 3 supplementation dose successfully increased their 25(OH)D levels and improved HRQL measures.
